Contact
searchSearch
HMP Global
Login

Myelofibrosis (ASH)

Updates in Myelofibrosis
From the ASH Annual Meeting & Exposition

Conference Coverage
Bromodomain and BET Inhibitor INCB057643 Shows Benefit for Patients With Myelofibrosis  
12/19/2024
According to research presented by Justin Watts, MD, at the 2024 ASH Annual Meeting & Exposition in San Diego, California, INCB057643 may improve patient outcomes in the treatment of hematologic malignancies including myelofibrosis.
According to research presented by Justin Watts, MD, at the 2024 ASH Annual Meeting & Exposition in San Diego, California, INCB057643 may improve patient outcomes in the treatment of hematologic malignancies including myelofibrosis.
According to research presented...
12/19/2024
Oncology
Firas El Chaer, MD
Conference Coverage
Nuvisertib Demonstrates Durable Clinical Activity for Patients With R/R Myelofibrosis
12/19/2024
According to data presented at the 66th ASH Annual Meeting by Firas El Chaer, MD, oral investigational highly selective PIM1 kinase inhibitor nuvisertib was well-tolerated and demonstrated clinical activity among patients with MF.
According to data presented at the 66th ASH Annual Meeting by Firas El Chaer, MD, oral investigational highly selective PIM1 kinase inhibitor nuvisertib was well-tolerated and demonstrated clinical activity among patients with MF.
According to data presented at...
12/19/2024
Oncology
Lucia Masarova, MD
Conference Coverage
Exploring Add-on Therapy With CK0804 for Patients With Myelofibrosis With Suboptimal Response to Ruxolitinib
12/19/2024
According to data presented at the 66th ASH Annual Meeting by Lucia Masarova, MD, CXCR4-enriched T regulatory cell therapy (CK0804) as an addition to ruxolitinib treatment demonstrated initial safety and promising clinical activity for...
According to data presented at the 66th ASH Annual Meeting by Lucia Masarova, MD, CXCR4-enriched T regulatory cell therapy (CK0804) as an addition to ruxolitinib treatment demonstrated initial safety and promising clinical activity for...
According to data presented at...
12/19/2024
Oncology
News
Combination of PXS-5505 With Standard Ruxolitinib Therapy Shows Potential Benefit for Patients With Myelofibrosis
12/16/2024
According to data presented at the 66th ASH Annual Meeting, the addition of PXS-5505 to ruxolotinib therapy demonstrated safety and potential efficacy for patients with myelofibrosis.
According to data presented at the 66th ASH Annual Meeting, the addition of PXS-5505 to ruxolotinib therapy demonstrated safety and potential efficacy for patients with myelofibrosis.
According to data presented at...
12/16/2024
Oncology
Conference Coverage
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Myelofibrosis
12/07/2024
According to data presented at the 2024 ASH Annual Meeting, assessed outcomes after allogeneic HCT were found to be acceptable among older patients with myelofibrosis.
According to data presented at the 2024 ASH Annual Meeting, assessed outcomes after allogeneic HCT were found to be acceptable among older patients with myelofibrosis.
According to data presented at...
12/07/2024
Oncology
Conference Coverage
Novel JAK2 Inhibitor OB756 Treatment Well-Tolerated Among Patients With Myelofibrosis
12/07/2024
According to results from a multicenter phase 1/2 trial, novel small molecule Janus kinase 2 (JAK2) inhibitor OB756 was found to be well-tolerated and demonstrated meaningful clinical activity among patients with MF.
According to results from a multicenter phase 1/2 trial, novel small molecule Janus kinase 2 (JAK2) inhibitor OB756 was found to be well-tolerated and demonstrated meaningful clinical activity among patients with MF.
According to results from a...
12/07/2024
Oncology
Conference Coverage
Bomedemstat Combined With Ruxolitinib Demonstrates Benefit Among Patients With Myelofibrosis
12/06/2024
According to results from a phase 2 study, the addition of bomedemstat to a ruxolitinib regimen was well-tolerated, improved splenomegaly and symptom scores, and stabilized hemoglobin both in the frontline and second-line setting for patients...
According to results from a phase 2 study, the addition of bomedemstat to a ruxolitinib regimen was well-tolerated, improved splenomegaly and symptom scores, and stabilized hemoglobin both in the frontline and second-line setting for patients...
According to results from a...
12/06/2024
Oncology
Conference Coverage
Second-Line Fedratinib Shows Promise for Patients With Myelofibrosis With Low Baseline Platelet Counts
12/05/2024
According to the phase 3 randomized FREEDOM2 Trial, fedratinib demonstrated spleen volume reduction and symptom reduction versus best available therapy among patients with myelofibrosis previously treated with ruxolitinib.
According to the phase 3 randomized FREEDOM2 Trial, fedratinib demonstrated spleen volume reduction and symptom reduction versus best available therapy among patients with myelofibrosis previously treated with ruxolitinib.
According to the phase 3...
12/05/2024
Oncology
Douglas Tremblay, MD
Conference Coverage
Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis
01/03/2024
At the ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.
At the ASH Annual Meeting,...
01/03/2024
Oncology
Claire Harrison, MD, FRCP, Guy’s and St. Thomas’ NHS Foundation Trust
Conference Coverage
Ruxolitinib Therapy Demonstrates Reduced JAK2 Allele Burden and Improvement in Hematocrit Control and Symptom Burden for Patients With PV
12/21/2023
At the 65th ASH Annual Meeting in San Diego, California, Claire Harrison, MD, FRCP discussed a pooled efficacy analysis that provided further evidence of the benefit of ruxolitinib treatment for patients with polycythemia vera, with or...
At the 65th ASH Annual Meeting in San Diego, California, Claire Harrison, MD, FRCP discussed a pooled efficacy analysis that provided further evidence of the benefit of ruxolitinib treatment for patients with polycythemia vera, with or...
At the 65th ASH Annual Meeting...
12/21/2023
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use